Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M

ZEVRA THERAPEUTICS, INC.

Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.
PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.
Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.
Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.